Begin main content


Last Updated: February 20, 2020
Result type: Reports
Project Number: SR0632-000
Product Line: Common Drug Review

Generic Name: brolucizumab

Brand Name: TBC

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Indications: Macular degeneration, age-related

Manufacturer Requested Reimbursement Criteria1: For the treatment of neovascular (wet) age-related macular degeneration.

Submission Type: New

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input postedAugust 28, 2019
Patient group input closedOctober 18, 2019

- Patient input submission received from Canadian Council of the Blind, CNIB Foundation, Fighting Blindness Canada, Vision Loss Rehabilitation Canada (Joint Submission)

Patient input summary sent for review to patient input groupsDecember 04, 2019
Patient group comments on input summary closedDecember 11, 2019

- No patient input summary feedback received

Submission receivedSeptember 26, 2019
Submission acceptedNovember 28, 2019

- Submission was not accepted for review on 10-Oct-2019

- Revised category 1 requirements received on 25-Nov-2019

Review initiatedNovember 29, 2019
Draft CADTH review report(s) sent to sponsorFebruary 20, 2020
Comments from sponsor on draft CADTH review report(s) receivedMarch 02, 2020
CADTH review team's comments on draft CADTH review report(s) sent to sponsorApril 02, 2020
Canadian Drug Expert Committee (CDEC) meetingApril 15, 2020
CDEC recommendation sent to sponsor and drug plansApril 27, 2020
April 29, 2020